Table 2.
Relationship between clinical characteristics of ovarian cancer patients and the expression of LPAR1-3
| Total (N) | LPAR1-Positive (%) | P value | LPAR2- Positive (%) | P value | LPAR3-Positive (%) | P value | |
|---|---|---|---|---|---|---|---|
| 52 | 36 (69.23) | 22 (42.31) | 9 (17.31) | ||||
| Histological subtypes | 0 | 0.664 | 0.587 | 0.542 | |||
| Serous | 26 | 20 (76.925) | 11 (42.31) | 4 (15.38) | |||
| Mucinous | 8 | 5 (62.5 %) | 3 (37.50) | 2 (25.00) | |||
| Endometroid | 12 | 7 (58.33 %) | 4 (33.33) | 3 (25.00) | |||
| Clear cell/Undifferentiated | 6 | 4 (66.67 %) | 4 (66.67) | 0 (0) | |||
| Differentiation | 0.415 | 0.002* | 0.034* | ||||
| High | 13 | 10 (76.92) | 2 (15.38) | 2 (15.38) | |||
| Moderate | 20 | 12 (60.00) | 6 (30.00) | 2 (10.00) | |||
| Poor | 19 | 14 (73.68) | 14 (73.68) | 5 (26.32) | |||
| Clinical stage | 0.003* | 0.712 | 0.678 | ||||
| FIGO I | 6 | 1 (16.67) | 3 (50.00) | 2 (33.33) | |||
| FIGO II | 8 | 4 (50.00) | 3 (37.5) | 2 (25.00) | |||
| FIGO III | 28 | 21 (75.00) | 12 (42.86) | 4 (14.29) | |||
| FIGO IV | 10 | 10 (100.00) | 4 (40.00) | 1 (10.00) |
* P <0.05 indicates statistically significant difference